Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
RESEARCH TOOLSreports
Allogene Therapeutics (ALLO) Stock Price & Analysis
884 Followers
ALLO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.88 - $11.10
Previous Close$3.19
Volume976.38K
Average Volume (3M)1.74M
Market Cap
$534.73M
Enterprise Value$134.59M
Total Cash (Recent Filing)$491.96M
Total Debt (Recent Filing)$91.82M
Price to Earnings (P/E)-1.3
Beta1.38
Next Earnings
Nov 08, 2023EPS Estimate
-$0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.45
Shares Outstanding167,626,365
10 Day Avg. Volume1,227,158
30 Day Avg. Volume1,738,710
Standard Deviation0.20
R-Squared0.05
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.86
Price to Sales (P/S)12343.40
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue700.97
Enterprise Value/Gross Profit553.86
Enterprise Value/Ebitda-0.39
Forecast
1Y Price Target
$15.00Price Target Upside387.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Allogene Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALLO FAQ
What was Allogene Therapeutics Inc’s price range in the past 12 months?
Allogene Therapeutics Inc lowest stock price was $2.88 and its highest was $11.10 in the past 12 months.
What is Allogene Therapeutics Inc’s market cap?
Currently, no data Available
When is Allogene Therapeutics Inc’s upcoming earnings report date?
Allogene Therapeutics Inc’s upcoming earnings report date is Nov 08, 2023 which is in 21 days.
How were Allogene Therapeutics Inc’s earnings last quarter?
Allogene Therapeutics Inc released its earnings results on Aug 03, 2023. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.589 by $0.059.
Is Allogene Therapeutics Inc overvalued?
According to Wall Street analysts Allogene Therapeutics Inc’s price is currently Undervalued.
Does Allogene Therapeutics Inc pay dividends?
Allogene Therapeutics Inc does not currently pay dividends.
What is Allogene Therapeutics Inc’s EPS estimate?
Allogene Therapeutics Inc’s EPS estimate is -$0.52.
How many shares outstanding does Allogene Therapeutics Inc have?
Allogene Therapeutics Inc has 167,626,360 shares outstanding.
What happened to Allogene Therapeutics Inc’s price movement after its last earnings report?
Allogene Therapeutics Inc reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.589. Following the earnings report the stock price went up 9.595%.
Which hedge fund is a major shareholder of Allogene Therapeutics Inc?
Among the largest hedge funds holding Allogene Therapeutics Inc’s share is PRIMECAP Management Co. It holds Allogene Therapeutics Inc’s shares valued at 28M.
---
Allogene Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (387.01% Upside)
$15.00 (387.01% Upside)
Blogger Sentiment
Bullish
ALLO Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $42.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.93%
12-Months-Change
Fundamentals
Return on Equity
-49.79%
Trailing 12-Months
Asset Growth
-18.64%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Allogene Therapeutics Inc
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
---
Top 5 ETFs holding ALLO
Vanguard Total Stock Market ETF
$12.29M
Vanguard Health Care ETF
$985.02K
Schwab U.S. Broad Market ETF
$142.88K
iShares Russell 3000 ETF
$78.40K
Vanguard Russell 3000 ETF
$18.49K
Up to five ETFs with an Outperform Smart Score that hold ALLO. The ETFs are listed according to market value of ALLO within the ETF
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Editas Medicine
―
Intellia Therapeutics
―
---